Freddie C. Hamdy
Research Subjects
Freddie C. Hamdy has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- David Edgar Neal
Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK
3 shared publications Mary C. Robinson
Department of Pathology, Freeman Hospital, Newcastle upon Tyne, United Kingdom
2 shared publicationsAlex Faulkner
Department of Social Medicine, University of Bristol, Canynge Hall, Bristol BS8 2PR, bBristol Urological Institute, Southmead Hospital, Bristol BS10 5NB, cUniversity Urology Unit, Freeman Hospital, Newcastle upon Tyne, NE7 7DN
1 shared publicationC H Horne
1 shared publicationC N Robson
1 shared publicationColin Marsh
Department of Pathology, Freeman Hospital, Newcastle upon Tyne, United Kingdom
1 shared publication
Latest Publications
Dilemmas in treating early prostate cancer: the evidence and a questionnaire survey of consultant urologists in the United Kingdom
Editorial by Emberton Evidence based medicine suggests that evidence of effectiveness should accumulate, preferably from randomised controlled trials, before treatments for any condition become widely used. The case of localised prostate cancer shows how difficult this can be in practice. The suitability of population screening for localised prostate cancer has been debated, 1 2 with particular concerns about the comparative effectiveness of the main treatments for the disease: radical prostatectomy, radical radiotherapy, and conservative management (also known as watchful waiting or surveillance). 3 4 Systematic reviews show that published evidence is limited to two seriously flawed randomised controlled trials and a range of observational studies with biases relating to patient selection, variable treatment techniques, outcome assessments, and methods of data analysis.3 These studies show that 10 year survival is good and overlaps for the three treatments, being 85-90% for radical prostatectomy, 65-90% for radical radiotherapy, and 70-90% for conservative management.3 Although some studies indicate a survival advantage of radical treatments in some patients, this advantage is small and uncertain given the particular study designs. Furthermore, …
Dilemmas in treating early prostate cancer: the evidence and a questionnaire survey of consultant urologists in the United Kingdom
Editorial by Emberton Evidence based medicine suggests that evidence of effectiveness should accumulate, preferably from randomised controlled trials, before treatments for any condition become widely used. The case of localised prostate cancer shows how difficult this can be in practice. The suitability of population screening for localised prostate cancer has been debated, 1 2 with particular concerns about the comparative effectiveness of the main treatments for the disease: radical prostatectomy, radical radiotherapy, and conservative management (also known as watchful waiting or surveillance). 3 4 Systematic reviews show that published evidence is limited to two seriously flawed randomised controlled trials and a range of observational studies with biases relating to patient selection, variable treatment techniques, outcome assessments, and methods of data analysis.3 These studies show that 10 year survival is good and overlaps for the three treatments, being 85-90% for radical prostatectomy, 65-90% for radical radiotherapy, and 70-90% for conservative management.3 Although some studies indicate a survival advantage of radical treatments in some patients, this advantage is small and uncertain given the particular study designs. Furthermore, …
- 1 December 1998
- Published by Wiley in The Prostate
- Vol. 37 (4) , 223-229
Expression of Bcl-2, Bax, and p53 in high-grade prostatic intraepithelial neoplasia and localized prostate cancer: relationship with apoptosis and proliferation
BACKGROUND Apoptosis-regulating genes have been shown to be important in the biology of prostate cancer. The aim of this study was to examine and correlate the expression of the apoptosis-regulating genes bcl-2, bax, and p53 with the frequency of apoptosis and rate of proliferation in benign prostatic epithelium (BP), prostate cancer, and high-grade prostatic intraepithelial neoplasia (HGPIN), which is currently considered the most likely precursor of prostate cancer. METHODS Forty-four patients with histologically proven prostate cancer were investigated. All the men underwent radical prostatectomy. Immunohistochemistry was performed to assess expression of bcl-2, bax, and p53, and proliferation rate, as measured by the Ki-67 index. The frequency of apoptotic bodies was assessed by morphological criteria. RESULTS The apoptotic index (AI) was highest in prostate cancer, and was significantly greater in HGPIN compared to benign prostate. The Ki-67 index was greatest in cancer, intermediate in HGPIN, and lowest in BP. The AI was increased in areas of BP in patients treated with neoadjuvant androgen ablation. No change in AI was seen in treated cases of HGPIN or cancer. Accumulation of p53 protein was infrequent in prostate cancer (2/43: 4.6%), and was absent in HGPIN. Bcl-2 overexpression was present in 2.3% of cancers (1/43) and in 34.9% of cases of HGPIN (15/43). Bax expression was seen in all cases of cancer and HGPIN. There was no correlation between bcl-2 expression and the apoptotic and Ki-67 indices in HGPIN. CONCLUSIONS p53 and bcl-2 expression is infrequent in clinically organ confined prostate cancer. Bcl-2 expression is significantly higher in HGPIN than in both the associated prostate cancer and BP. The AI and Ki-67 index appeared intermediate in the putative precursor lesion HGPIN compared to prostate cancer and BP. Prostate 37:223–229, 1998.
- 1 December 1998
- Published by Wiley in The Prostate
- Vol. 37 (4) , 223-229
Expression of Bcl-2, Bax, and p53 in high-grade prostatic intraepithelial neoplasia and localized prostate cancer: relationship with apoptosis and proliferation
BACKGROUND Apoptosis-regulating genes have been shown to be important in the biology of prostate cancer. The aim of this study was to examine and correlate the expression of the apoptosis-regulating genes bcl-2, bax, and p53 with the frequency of apoptosis and rate of proliferation in benign prostatic epithelium (BP), prostate cancer, and high-grade prostatic intraepithelial neoplasia (HGPIN), which is currently considered the most likely precursor of prostate cancer. METHODS Forty-four patients with histologically proven prostate cancer were investigated. All the men underwent radical prostatectomy. Immunohistochemistry was performed to assess expression of bcl-2, bax, and p53, and proliferation rate, as measured by the Ki-67 index. The frequency of apoptotic bodies was assessed by morphological criteria. RESULTS The apoptotic index (AI) was highest in prostate cancer, and was significantly greater in HGPIN compared to benign prostate. The Ki-67 index was greatest in cancer, intermediate in HGPIN, and lowest in BP. The AI was increased in areas of BP in patients treated with neoadjuvant androgen ablation. No change in AI was seen in treated cases of HGPIN or cancer. Accumulation of p53 protein was infrequent in prostate cancer (2/43: 4.6%), and was absent in HGPIN. Bcl-2 overexpression was present in 2.3% of cancers (1/43) and in 34.9% of cases of HGPIN (15/43). Bax expression was seen in all cases of cancer and HGPIN. There was no correlation between bcl-2 expression and the apoptotic and Ki-67 indices in HGPIN. CONCLUSIONS p53 and bcl-2 expression is infrequent in clinically organ confined prostate cancer. Bcl-2 expression is significantly higher in HGPIN than in both the associated prostate cancer and BP. The AI and Ki-67 index appeared intermediate in the putative precursor lesion HGPIN compared to prostate cancer and BP. Prostate 37:223–229, 1998.
- 4 May 1998
- Published by Wiley in The Journal of Pathology
- Vol. 185 (1) , 108-111
The immunohistochemical detection of cripto‐1 in benign and malignant human bladder
- 4 May 1998
- Published by Wiley in The Journal of Pathology
- Vol. 185 (1) , 108-111
The immunohistochemical detection of cripto‐1 in benign and malignant human bladder
- 1 October 1997
- Vol. 57 (19) , 4427-31
Immunolocalization and messenger RNA expression of bone morphogenetic protein-6 in human benign and malignant prostatic tissue.
Skeletal metastases are common in advanced prostate cancer, causing considerable morbidity, and they are usually osteoblastic in nature with no clear explanation for this phenomenon. Bone morphogenetic proteins (BMPs) induce bone formation in vivo, and preliminary work showed a possible association between BMPs and prostatic skeletal metastases; differential expression favors BMP-6 as a potential new marker and mediator of osteosclerotic deposit formation. We investigated BMP-6 mRNA and protein expression by in situ hybridization and immunohistochemistry in malignant and benign prostates from 40 men. BMP-6 mRNA expression was detected exclusively in malignant epithelial cells in 20 of 21 patients (95%) with metastases and in 2 of 11 patients (18%) with localized cancer, and it was absent in 8 benign samples. Immunostaining for BMP-6 was predominantly cytoplasmic and was present in all primary tumors with established metastases and in 4 of 11 (36%) organ-confined cancers. In benign prostatic hyperplasia, basal cells and areas of basal cell hyperplasia were positive for BMP-6 by immunohistochemistry. The results suggest a close association between BMP-6 expression in primary malignant prostatic tissue and skeletal metastases. BMP-6 may be responsible, in part, for the osteoblastic changes in metastatic lesions secondary to prostate cancer.
- 1 October 1997
- Vol. 57 (19) , 4427-31
Immunolocalization and messenger RNA expression of bone morphogenetic protein-6 in human benign and malignant prostatic tissue.
Skeletal metastases are common in advanced prostate cancer, causing considerable morbidity, and they are usually osteoblastic in nature with no clear explanation for this phenomenon. Bone morphogenetic proteins (BMPs) induce bone formation in vivo, and preliminary work showed a possible association between BMPs and prostatic skeletal metastases; differential expression favors BMP-6 as a potential new marker and mediator of osteosclerotic deposit formation. We investigated BMP-6 mRNA and protein expression by in situ hybridization and immunohistochemistry in malignant and benign prostates from 40 men. BMP-6 mRNA expression was detected exclusively in malignant epithelial cells in 20 of 21 patients (95%) with metastases and in 2 of 11 patients (18%) with localized cancer, and it was absent in 8 benign samples. Immunostaining for BMP-6 was predominantly cytoplasmic and was present in all primary tumors with established metastases and in 4 of 11 (36%) organ-confined cancers. In benign prostatic hyperplasia, basal cells and areas of basal cell hyperplasia were positive for BMP-6 by immunohistochemistry. The results suggest a close association between BMP-6 expression in primary malignant prostatic tissue and skeletal metastases. BMP-6 may be responsible, in part, for the osteoblastic changes in metastatic lesions secondary to prostate cancer.
- 1 January 1995
- Published by Wiley in Neurourology and Urodynamics
- Vol. 14 (4) , 359-363
Transrectal ultrasound guided needle electromyography of the urethral sphincter in males
- 1 January 1995
- Published by Wiley in Neurourology and Urodynamics
- Vol. 14 (4) , 359-363
Transrectal ultrasound guided needle electromyography of the urethral sphincter in males